Deals For Genetic Data Raise Issues of Privacy, Sharing
By John Lauerman and Makiko Kitamura,
Bloomberg
| 01. 14. 2015
Untitled Document
In three recent deals, drugmakers are betting that personal genetic maps will finally fulfill their early promise to unlock secrets and cure diseases.
At the same time, the agreements revived questions about privacy protections and how useful personal genetic data will prove to be.
Roche Holding AG (RHHBY) committed $1 billion to take control of Foundation Medicine Inc. (FMI), which sequences genes of cancer patients, aiming to customize treatment. Roche’s Genentech unit said it would pay as much as $60 million for access to 23andMe Inc.’s data on customers with Parkinson’s disease. And Pfizer Inc. (PFE) reached a deal that will allow the drugmaker to analyze personal genetic information from 650,000 23andMe customers, without giving terms.
The pacts, together with 23andMe’s announcement that it will enter into partnerships with eight other companies this year, boosted confidence in the commercial value of gene mapping. Since the first draft of a full human genome was deciphered in 2001, researchers have predicted breakthroughs in understanding the origins of disease, only to be frustrated as business developed slowly and regulatory issues...
Related Articles
GeneWatch UK has prepared a briefing on the genetic modification of nature for the International Union for Conservation of Nature (IUCN) Congress in October 2025
The upcoming Congress claims to be “where the world comes together to set priorities and drive conservation and sustainable development action.” A major concern for those on the outside is that the Congress may advance plans to develop and encourage the use of synthetic biology in nature conservation. This could at first glance sound like...
By Aaron Ginn, The Washington Post | 09.12.2025
Earlier this year, I had dinner in D.C. with Jensen Huang, the president and chief executive of Nvidia. At one point, he said something that struck me: “Why is everyone here so negative?”
He wasn’t referring to the economy...
By Roni Caryn Rabin, The New York Times | 08.25.2025
Scientists have dreamed for centuries about using animal organs to treat ailing humans. In recent years, those efforts have begun to bear fruit: Researchers have begun transplanting the hearts and kidneys of genetically modified pigs into patients, with varying degrees...
The Center for Genetics and Society is delighted to recommend the current edition of GMWatch Review – Number 589. UK-based GMWatch, a long-standing ally, was founded in 1998 by Jonathan Matthews as an independent organization seeking to counter the enormous corporate political power and propaganda of the GMO industry and its supporters. Matthews and Claire Robinson are its directors and managing editors.
CGS works to ensure that social justice, equity, human rights, and democratic governance are front...
